Navigation Links
Safinamide Phase III Study Results Presented at 2013 MDS Meeting
Date:6/18/2013

icial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions.

Newron does not undertake any obligation to publicly up-date or revise forward looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed.

This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.


'/>"/>
SOURCE Newron Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
2. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
3. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
4. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
5. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
6. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
7. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
8. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
9. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
10. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
11. SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - a ... to place and insert the screw accurately - offers ... ligament) repair or reconstruction as it holds the bones ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw ...
(Date:1/14/2014)... Jan. 14, 2014 NineSigma , Inc., the ... Innovation Leadership Summit , May 14-16, 2014 at ... Cleveland Ohio . This is ... committed to breakthrough achievements through open innovation. Participants will ...
(Date:1/14/2014)... 2014   Evidera , a leading provider of evidence-based ... for Drug Evaluation and Research (CDER), U.S. Food and ... document for a patient-reported outcome (PRO) measure in drug ... Tool [EXACT] for Measurement of Symptoms of Acute Bacterial ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Schein, Inc. (Nasdaq: HSIC ), the largest provider ... today that it will release its first quarter 2011 financial ... 2011, and will provide a live webcast of its earnings ... Eastern Daylight Time. Speakers on the call will include Stanley ...
... NASHVILLE, Tenn., April 19, 2011 Cumberland Pharmaceuticals ... pharmaceutical company focused on hospital acute care and gastroenterology ... agreement to acquire the rights to ifetroban, a new ... development under the brand name Hepatoren™ (ifetroban) Injection and ...
Cached Medicine Technology:Henry Schein to Webcast First Quarter 2011 Conference Call Tuesday, May 3, at 10:00 a.m. EDT 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 4
(Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... from Montefiore Medical Center and the ... will present new findings at the Alzheimer,s Association International ... in Copenhagen, Denmark. Data from the four abstracts will ... normality to mild cognitive impairment and dementia. The research ... established in 1980 to examine healthy brain aging as ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
(Date:7/9/2014)... age with kidney and heart disease have raised concerns ... adults. However, in the first study to look closely ... Medicine at the University of Pennsylvania report that older ... expectancy and cardiovascular health as very healthy older people ... the ever increasing organ transplant waitlists, the authors of ...
Breaking Medicine News(10 mins):Health News:Wake-up call for more research into cell metabolism 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
... in effort to drop pounds, experts say , TUESDAY, Nov. ... exercise and diet are crucial. But a new study says ... the number of TVs in your house and the presence ... out as a stronger factor than we would have anticipated," ...
... Nov. 3 EntreMed, Inc. (Nasdaq: ENMD ... the treatment of cancer today announced presentations for ... AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ... Boston, Massachusetts. Presentations are listed below. , ...
... China, Nov. 3 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain,Drugstore Ltd. (NYSE: ... chain in China based on the number of directly operated ... agreement,with ATMU (China) Technology Co., Ltd., a subsidiary of ATMU ... ATMs in Nepstar stores. , This ...
... 44-year-old woman will celebrate many future birthdays thanks to the ... for breast cancer. , Dr. Sweeten, a board-certified gynecologist and ... incorporated the Provista Life Science BT Test®, a blood test ... practice. Sweeten noted a case where a 44-year-old patient called ...
... ... the Health IT Standards Committee hearing held in Washington, D.C. last week, which was a ... ... Health Inc. endorses and commends the efforts of the Health IT Standards Committee hearing ...
... ... Oven for PTA and PTCA Catheters is Compact, Easy to Operate and Cost Effective ... Laguna Niguel, ... provides a cost-effective approach to heat treating of wrapped balloons on balloon catheters ...
Cached Medicine News:Health News:Living With Less TV, More Sweat Boosts Weight Loss 2Health News:Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference 2Health News:Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference 3Health News:China Nepstar Enters Into Strategic Cooperation Agreement with ATMU to Install More Than 1,000 ATMs in Nepstar Stores 2Health News:China Nepstar Enters Into Strategic Cooperation Agreement with ATMU to Install More Than 1,000 ATMs in Nepstar Stores 3Health News:A Breast Cancer Test That Saves Lives 2Health News:A Breast Cancer Test That Saves Lives 3Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 2Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 3Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 4Health News:Interface new Balloon Catheter Solutions PTA and PTCA Catheters 2
Straight shafts with 4 mm platform. Wide serrated handle with dull finish. Platform straight....
Curved shafts with 2 mm angled platform. Wide serrated handle with dull finish....
Straight shafts with micro tips and sandblast finish. Insulated smooth handle....
Double-ended. 12 mm bayonet shaped blade. 10 mm curved blade....
Medicine Products: